NASA SBIR 2008 Solicitation


PROPOSAL NUMBER: 08-2 X10.01-9543
SUBTOPIC TITLE: In Flight Diagnosis and Treatment
PROPOSAL TITLE: Thioaptamer Diagnostic System

SMALL BUSINESS CONCERN (Firm Name, Mail Address, City/State/Zip, Phone)
AM Biotechnologies, LLC
12521 Gulf Freeway
Houston, TX 77034 - 4509
(832) 295-1483

PRINCIPAL INVESTIGATOR/PROJECT MANAGER (Name, E-mail, Mail Address, City/State/Zip, Phone)
Xianbin Yang
12521 Gulf Freeway
Houston, TX 77034 - 4509
(832) 379-2175

Expected Technology Readiness Level (TRL) upon completion of contract: 4 to 5

TECHNICAL ABSTRACT (Limit 2000 characters, approximately 200 words)
AM Biotechnologies (AM) in partnership with Sandia National Laboratories will develop a Thioaptamer Diagnostic System (TDS) in response to Topic X10.01 Reusable Diagnostic Lab Technology. The TDS will quickly quantify clinically relevant biomarkers in flight using only microliters of virtually any complex sample. The system combines ambient-stable, long-shelf-life affinity agent assays with a handheld microfluidic gel electrophoresis affinity assay quantification technology. The system is easy to use, compatible with operation in microgravity, and designed to permit simultaneous quantification of 32 or more biomarkers from a single astronaut sample.

Phase 1 of this project demonstrated that a thioaptamer assay used in the microfluidic instrument can quantify a specific biomarker in serum in the low nanomolar range. AM also successfully identified novel affinity agents to bone specific alkaline phosphatase (BAP) and demonstrated their use to detect BAP using the microfluidic instrument. Phase 2 will expand the number of ambient stable affinity agents and demonstrate a TDS prototype to NASA. AM anticipates that the TDS at the end of Phase 2 will be at TRL 4 to 5. In Phase 3, AM and Sandia will produce flight units for NASA research use on the International Space Station (ISS) as well as for diagnostic use on future long duration missions.

POTENTIAL NASA COMMERCIAL APPLICATIONS (Limit 1500 characters, approximately 150 words)
Successful development of this system will provide NASA with both near-term as well as long-term advantages. Near-term, a non-clinical version of the system will be extraordinarily useful for conducting research on ISS into human adaptation to microgravity. The TDS could monitor levels of numerous biomarkers in astronauts on orbit and would eliminate the need to freeze samples on orbit and return them to Earth for ground-based testing. Long-term, the clinical version of the TDS will provide a robust, flight tested diagnostic capability for missions to the moon and Mars. Virtually any type of ambient stable assay that is of interest to NASA could be developed for the system.

POTENTIAL NON-NASA COMMERCIAL APPLICATIONS (Limit 1500 characters, approximately 150 words)
The Thioaptamer Diagnostic System will be commercialized first in the research support market, and then later as an FDA-approved hand-held clinical diagnostic system for non-traditional and resource poor locations. Clinical TDS units will be targeted for use in physician offices and by emergency responders. Research support market units will be targeted at lower-throughput biomedical research laboratories in universities and companies with limited capital budgets that have limited or no access to core support laboratories.

NASA's technology taxonomy has been developed by the SBIR-STTR program to disseminate awareness of proposed and awarded R/R&D in the agency. It is a listing of over 100 technologies, sorted into broad categories, of interest to NASA.

Biomedical and Life Support
Biomolecular Sensors
Portable Data Acquisition or Analysis Tools

Form Generated on 08-03-09 13:26